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Homozygous Nonsense Mutations in TWIST2
Cause Setleis Syndrome
Turgut Tukel,1,5,7 Drazen Sosic,2,5 Lihadh I. Al-Gazali,3 Mo´nica Erazo,1 Jose Casasnovas,4
Hector L. Franco,4 James A. Richardson,2 Eric N. Olson,2 Carmen L. Cadilla,4,6
and Robert J. Desnick1,6,*
The focal facial dermal dysplasias (FFDDs) are a group of inherited developmental disorders in which the characteristic diagnostic feature
is bitemporal scar-like lesions that resemble forceps marks. To date, the genetic defects underlying these ectodermal dysplasias have not
been determined. To identify the gene defect causing autosomal-recessive Setleis syndrome (type III FFDD), homozygosity mapping was
performedwith genomic DNAs from five affected individuals and 26members of the consanguineous Puerto Rican (PR) family originally
described by Setleis and colleagues. Microsatellites D2S1397 and D2S2968 were homozygous in all affected individuals, mapping the
disease locus to 2q37.3. Haplotype analyses of additional markers in the PR family and a consanguineous Arab family further limited
the disease locus to ~3 Mb between D2S2949 and D2S2253. Of the 29 candidate genes in this region, the bHLH transcription factor,
TWIST2, was initially sequenced on the basis of its known involvement in murine facial development. Homozygous TWIST2 nonsense
mutations, c.324C>T and c.486C>T, were identified in the affected members of the Arab and PR families, respectively. Characterization
of the expressed mutant proteins, p.Q65X and p.Q119X, by electrophoretic mobility shift assays and immunoblot analyses indicated
that they were truncated and unstable. Notably, Setleis syndrome patients and Twist2 knockout mice have similar facial features, indi-
cating the gene’s conserved role inmammalian development. Although human TWIST2 and TWIST1 encode highly homologous bHLH
transcription factors, the finding that TWIST2 recessivemutations cause an FFDD and dominant TWIST1mutations cause Saethre-Chot-
zen craniocynostosis suggests that they function independently in skin and bone development.The focal facial dermal dysplasias (FFDDs) are a group of
inherited syndromes characterized by distinctive bitempo-
ral scar-like depressions resembling forceps marks.1 Three
subtypes have been delineated on the basis of their clinical
features: type I FFDD, or Brauer syndrome (MIM 136500),
is inherited as an autosomal-dominant trait, and most
affected patients have only the characteristic bitemporal
lesions; type II FFDD (MIM 227260) is the autosomal-reces-
sive form of Brauer2 syndrome without additional
features;1 and type III FFDD, or Setleis syndrome (MIM
227260), first described in patients from consanguineous
Puerto Rican (PR) families,3 is characterized by bilateral
temporal marks and additional facial features, including
an aged-leonine appearance, absent eyelashes on both
lids or multiple rows on the upper lids, absent Meibomian
glands, slanted eyebrows, chin clefting, and other
nonfacial manifestations1,3–6 (Figure 1A). The disease is
panethnic, having been described in White, Hispanic,
Asian, and American Indian patients from North America,
Europe, Japan, theMiddle East, and Samoa.3,7–10 Themode
of inheritance of Setleis syndrome has been variably
reported as autosomal dominant (e.g., 11,12), autosomal
dominant with variable expressivity and decreased pene-
trance in families in which a parent had minimal to mild
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The Americparent had manifestations (e.g., 7,13–16), and autosomal
recessive (e.g., 1,3,5,17). These reports suggest that Setleis
syndrome is genetically heterogeneous, perhaps reflecting
the interactive nature of the underlying gene defects.
Histologically, the bitemporal lesion is a mesodermal
dysplasia with near absence of subcutaneous fat and with
skeletal muscle almost contiguous with the epidermis,6
suggesting insufficient migration of neural crest cells into
the frontonasal process and the first branchial arch.4 To
date, the genetic bases of the FFDDs have not been identi-
fied. Here, we report that homozygous TWIST2 (MIM
607556) nonsense mutations, identified by positional
cloning, cause Setleis syndrome. TWIST2 is a member of
the bHLH transcription factor family first described in
mice (Dermo1),18 whose function has been characterized
in knockout (KO) mice.19
For identification of the Setleis syndrome locus,
a genome scan was performed on five affected individuals
and 26 family members from the original consanguineous
family from the San Sebastian and Lares regions of Puerto
Rico described by Setleis et al.3 (Figure 2). Informed
consent was provided by the subjects and/or their parents,
and each subject was examined and provided blood
samples. Several affected individuals provided skin biop-
sies and were photographed. Genomic DNAs were isolatedicine of New York University, New York, NY 10029, USA; 2Department of
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Figure 1. Similarity of Facial Characteristics of Setleis Syndrome Patients and Wild-Type and Twist2 Knockout Mice
(A) A 5-year-old affected PR male. Note leonine facial appearance, bitemporal lesions, and upper eyelash abnormalities.
(B) Twist2 knockout (KO) mice. Note similar facial and eye abnormalities, including bitemporal lesions (white arrowheads), narrow
snout, pointed chin, and sparse or absent eyelashes (black arrow).
(C) Wild-type 129/C57 mice. All mouse comparisons were performed on littermate controls.
(D and E) Hematoxylin- and eosin-stained skin sections of alopecic areas (D) and palpebral margins (E) at nictitating membrane (*) from
Twist2 KO and wild-type mice. Insets: Note absence of Meibomian glands, and decreased eyelash follicles. e ¼ epidermis; d ¼ dermis;
mg ¼ Meibomian gland; ey ¼ eyelid. Scale bars represent 200 mm in (E). Insets represent 40 mm in (D) and (E).with the Puregene Isolation Kit according to the manufac-
turer’s instructions (Gentra Systems, Minneapolis, MN,
USA). Cultured fibroblasts were established from skin
biopsies by standard procedures. Peripheral blood and/or
cultured fibroblasts also were obtained from patients and
members of four unrelated families with FFDD or Setleis
syndrome phenotypes. These included an Arab family8
and three United States families of Hispanic, German
Italian, and Cherokee Indian ancestry.
Linkage analysis was performed by genotyping 501
microsatellite markers at a 10 cM density (Genome-Wide
Screening Set, version 9, Single Chromosome Set, Invitro-
gen Life Technologies, Carlsbad, CA, USA) in genomic
DNAs from the five affected members of the PR family as290 The American Journal of Human Genetics 87, 289–296, August 1previously described.20 Microsatellite assays were analyzed
on a ABI Prism 3130xl Genetic Analyzer (Applied Biosys-
tems, Carlsbad, CA, USA) with GeneScan Analysis software
(version 3.1.2) and Genotyper software (version 2.5) (Per-
kin-Elmer-Cetus, Norwalk, CT, USA). Homozygousmarkers
in all five affected individuals were then genotyped in all
available family members for determination of their
segregation and for haplotype analyses. Additional
markers (D2S2344, D2S206, D2S1279, D2S2348,
D2S2973, D2S1397, D2S2968, D2S2285, D2S2253,
D2S125, D2S395, and D2S140) were genotyped, and the
critical region was further narrowed by haplotype analyses
of other putative FFDD families, including two informative
affected first cousins from a consanguineous Arab family3, 2010
Figure 2. Partial Pedigrees of a Large
Setleis Syndrome Family from Puerto Rico
Arrow indicates the five affected individ-
uals who were genotyped.from the United Arab Emirates.8 Linkage calculations were
made with the SimWalk2 program21 and were confirmed
with the Linkmap program.22
Only microsatellites D2S1397 and D2S2968 were homo-
zygous in all affected individuals from the PR family,
mapping the disease locus to 2q37.3 (Figure 3A). Saturation
of the region with additional markers further defined the
locus to 17 cM (~7 MB) between D2S206 and D2S2253
(LOD score Z ¼ 5.22 at D2S1397). These markers were
analyzed in three unrelated Setleis syndrome families.
Only the consanguineous Arab patients8 were homozygous
for the region, and their haplotypes further narrowed the
centromeric boundary, reducing the critical region to 8 cM
(~3 MB) between D2S2949 and D2S2253 (Figures 4A–4D),
which localized the Setleis syndromecritical regionbetween
238,061,150 and 241,439,288 bp on the chromosome 2
physical map. Inspection of the 29 genes in this region sug-
gested TWIST2 as an initial candidate for sequencing on theThe American Journal of Human Gebasis of the spatial and temporal
dermal facial expression pattern of
the murine ortholog during embryo-
genesis.18 The promoter, exonic, adja-
cent intronic, and 30 untranslated
regions of the TWIST2 gene were
amplified via PCR from genomic
DNAs of these patients and sequenced
on an ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems).
Sequencing of TWIST2 revealed
homozygous nonsense mutations in
the PR (c.486C>T [p.Q119X]) and
Arab (c.324C>T [p.Q65X]) patients
(Figure 3C), which segregated in
respective family members in an auto-
somal-recessive patternwith full pene-
trance. Both nonsense mutations
predicted early truncation of the
TWIST2 transcription factor;
the c.486C>T mutation truncated
the C-terminal region after the bHLH
motif, and the c.324C>T mutation
eliminated the bHLH region and the
C terminus (Figure 3D). Sequencing
of TWIST2 in five other unrelated
familial and/or sporadic Setleis
syndrome and FFDD patients did not
identify disease-causing mutations,
emphasizing the genetic heteroge-
neity of the bilateral temporal lesions
that characterize the Setleis syndrome
and FFDD phenotype.For characterization of the mRNA levels and truncated
proteins expressed by these mutations, Myc-tagged
constructs of wild-type and mutated (c.324C>T and
c.486C>T) TWIST2 cDNAs were prepared in the pCINEO
vector and used for transient transfection of HeLa cells.
Quantitative PCR revealed approximately 3-fold to 4-fold
decreased amounts of the c.324C>T and c.486C>T fibro-
blast mRNAs compared to wild-type levels (not shown).
The expressed TWIST2 c.324C>T and c.486C>T mutant
proteins in HeLa cells were unstable, consistent with the
decreased amounts of the p.Q119X protein and even less
of the p.Q65X mutant protein, detected by immunoblot
analysis (Figure 3E). The instability of both mutant tran-
scripts and their truncated proteins is consistent with
nonsense-mediated decay and might explain why the
patients with different mutations had similar phenotypes.
Twist2 KO mice on a 129 genetic background develop
cachexia and die within days after birth as a result ofnetics 87, 289–296, August 13, 2010 291
Figure 3. Mapping the Setleis Syndrome Gene
(A–C) Chromosome 2 cytogenetic map (A), critical region genes and TWIST2 gene structure29 (B), and electropherograms of c.324C>T
and c.486C>T mutations (C). Sequencing was performed on an ABI Prism 3730xl Capillary Array Sequencer with the use of ABI Prism
BigDye Terminator Ready Reaction Mix (Perkin-Elmer-Cetus). Electropherograms were inspected with ABI Prism Sequencing Analysis
software (version 3.4.1) and were aligned to the reference sequence with the BLAST engine.
(D and E) Cartoon depicting 160 amino acid TWIST2 protein domains; NLS, nuclear localization signal (D), and immunoblot analysis of
Myc-tagged normal and mutated (p.Q119X and p.Q65X) TWIST2 proteins expressed in HeLa cells (E). HeLa cells were transfected with
Lipofectamine 2000 reagent (Invitrogen). Equal amounts of total cell extracts from transfected cells were loaded for immunoblot anal-
ysis, and anti-Myc antibody (Sigma-Aldrich) was used to detect the tagged TWIST2 proteins according to manufacturer’s instructions.
(F) EMSA of TNF-a promoter E box oligonucleotide and recombinant Myc-tagged TWIST2 proteins. EMSA experiments were done with
in vitro translated proteins with the use of the TnT T7 Quick Coupled Transcription/Translation System (Promega) as previously
described.19elevated proinflammatory cytokines.19 However, Twist2
KO mice on a 129/C57 mixed background have a milder
phenotype, some attaining adulthood and living a normal292 The American Journal of Human Genetics 87, 289–296, August 1life span.19 Analysis of the 129/C57 KO mice revealed
a facial phenotype similar to that of Setleis syndrome
patients, including thin skin and sparse hair with bilateral3, 2010
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Table 1. Phenotypic Similarities of Setleis Syndrome Patients
and Twist2 Knockout Mice
Setleis Syndrome Patients Knockout Mice
Bitemporal lesions resembling
forceps marks
Alopecic areas between ears and
eyes
Absent lower eyelashes Absent lower eyelashes
Multiple rows of eyelashes in
upper eyelid
Multiple rows of eyelashes in
upper eyelid
Sparse hair Sparse hair
Abnormal pattern of hair growth Abnormal pattern of hair growth
Bulbous nasal tip Narrowing of the snout
Absent Meibomian glands Absent Meibomian glands
Protruding soft tissue in chin,
median ridge of the chin
Pointed chinpronounced alopecic areas between the ears and the eyes
resembling the bitemporal forceps marks in humans.
They also had absent lower eyelashes, narrow snouts,
protruding chins, short anterior-posterior head diameters,
and low-set dysmorphic ears (Figures 1B and 1C, Table 1).
Histologically, the bilateral alopecic areas in the KOmice
were similar to the defects in Setleis syndrome patients,4
including the hypoplastic dermis and absence of epidermal
appendages and subcutaneous fat (Figure 1D). In mice,
Twist2 is expressed in the dermis, not the epidermis,18
and the alopecic areas are located in the region with
predominantly mesoderm and not neural-crest-derived
dermis.23 The KO mice also have absent/hypoplastic
Meibomian glands (Figure 1E), as seen in Setleis syndrome
patients.5 Development of eyelids in mammals is governed
by bidirectional signaling between surface epithelium and
underlying neural-crest-derived mesenchyme.24 Mice with
Wnt1-Cre-mediated deletion of Twist2 do not show an
eyelid phenotype or bilateral head skin lesions (data not
shown), indicating that unlike Twist1, Twist2 does not
function in the cranial neural crest. We suggest that Twist2
is involved in cranial dermal mesenchyme development,
while indirectly regulating overlying epidermis and induc-
tion of its appendages. Furthermore, murine Twist2 and
human TWIST2 may regulate mesenchymal signal(s) for
migration and/or differentiation of neural crest cells
involved in Meibomian gland and eyelash development.
Thus, Twist2 KO mice provide an excellent model for the
investigation of its role in facial development.
ThemurineTwist2andhumanTWIST2proteinsare100%
identical, whereas their TWIST1 (MIM 601622) proteins
have 92% identity. Human TWIST1 and TWIST2 proteins
are 98% identical in the ~100 residues in the bHLH region
and C terminus (Figure 5). The main difference between
these two human proteins lies in the N terminus, whereFigure 4. Genetic Analysis of Chromosome 2 for the Puerto Rican
(A and B) Chromosome 2 haplotypes of PR family members.
(C) Haplotypes for the family from the United Arab Emirates.
(D) Plot of the LOD scores for chromosome 2q37.3.
294 The American Journal of Human Genetics 87, 289–296, August 1TWIST2 lacks two glycine-rich regions found in TWIST1.
Throughout their coding regions, the identity and similarity
are 65% and 71%, respectively. In mice, Twist1 is essential
for embryonic viability and cranial neural tube formation.25
In humans, TWIST1 haploinsufficiency causes Saethre-
Chotzen syndrome (MIM 101400).26
The bHLH proteins of the TWIST subfamily form hetero-
dimers with ubiquitous E proteins, such as E12, as well
as homodimers. For determining the DNA-binding proper-
ties of the TWIST2 mutated proteins, EMSA studies were
conducted with the wild-type and mutant proteins
p.Q65X and p.Q119X, as previously described.27 Relative
positions of TWIST homodimers, TWIST2/E12 hetero-
dimers, and supershifted complexes are shown in Figure 3F.
A 32P-labeled E box containing oligonucleotide derived
from the proximal region of the human TNF-a promoter
was used as a probe (50-GGGCCGACTACCGCTTCCTCC
AGATGAGCTCATGGGTTT-30). This probe is part of an
evolutionarily conserved DNA region upstream of the
TNF-a transcription start site that has been shown previ-
ously to bind both mouse Twist1 and Twist2 proteins.19
The gel mobility shift assays revealed that the human
TWIST2 protein bound to the DNA probes containing
a conserved E box, both as homodimers and as heterodimers
(Figure 3F). However, neither mutant protein was able to
bind a DNA probe as a homodimer. Mutant protein
p.Q119X, but not p.Q65X, bound DNA as a heterodimer,
albeit at reduced levels in comparison to full-length TWIST2
(Figure 3F). The outcome of this binding is unclear, because
the C terminus contains an important inhibitory domain
that can repress target gene transcription.19,27 Therefore,
the p.Q119X mutant protein could cause aberrant expres-
sion of target genes, given that its trans-activating effects
presumably differ from those of the wild-type protein. The
p.Q65X protein likely represents a true loss-of-function
mutant. Notably, the mouse phenotypes of the Twist1 null
mutantandthemutantwithC-terminalmutations (‘‘Charlie
Chaplin’’ strain) differ significantly.28 We speculate that
dominant-negativemutations inTWIST2orpartnerproteins
could cause autosomal-dominant inheritance of FFDD.
Insummary, Setleis syndromeresults fromTWIST2homo-
zygous nonsense mutations that affect TWIST2 protein
stability and DNA binding, providing the first genetic basis
for an FFDD syndrome. The similar facial dysmorphia in
Twist2 KO mice demonstrates the conservation of TWIST2
function in mammalian facial dermal development. Thus,
Twist2 KO mice represent an appropriate animal model for
the study of the molecular mechanism(s) leading to the
FFDD syndromes. Our results suggest that TWIST2 binding
partners or other dermal-development transcription factors
may be defective in other Setleis syndrome patients or
FFDD syndromes.and United Arab Emirates Setleis Syndrome Families
3, 2010
Figure 5. Alignment of the Human
TWIST1 and TWIST2 Amino Acid
Sequences
The functional domains and residues are
indicated where disease-causing TWIST1
or TWIST2 nonsense (X) or missense
(arrows with substituted amino acids)
mutations occurred in Saethre-Chotzen
syndrome and Setleis syndrome, respec-
tively. Solid bars indicate functional
domain regions. Amino acid identity (*),
conserved substitutions (:), and semicon-
served substitutions ($) are indicated below
the TWIST2 residues.Acknowledgments
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